long intergenic non-protein coding RNA 2636Genealiases: []
Q-omics provides the consensus-scored LINC02636 profile across patient tissues and cancer cell-line models. LINC02636 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, LINC02636 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, LINC02636 RNA expression shows 13,398 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, BRCA, and THYM as cancer lineages where LINC02636 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02636 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02636 survival associations across molecular data types. LINC02636 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02636 RNA expression–survival associations across cancer types. High LINC02636 expression shows unfavorable associations in DLBC, ACC and LUAD, but favorable associations in LGG, UCS and LUSC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for LINC02636 RNA expression.
This table summarizes LINC02636 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02636. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02636 shows lower tumor expression in BRCA and higher tumor expression in LIHC, CHOL, LUSC, PRAD and HNSC. The BRCA box plot shows higher LINC02636 RNA expression in normal versus tumor tissue (log2 FC = −0.449, t-test p < 0.001).
This table shows molecular features associated with LINC02636 in patient tissues and cancer cell lines. In patient samples, LINC02636 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
